Portfolio
Companies built, assets stewarded.
A selection of the companies and assets across our €874M platform. We hold many positions in confidence; those featured here illustrate the breadth of our activity and the conviction behind it.
Our portfolio spans operating companies and real assets, software and science, control acquisitions and minority growth positions. What unites them is a long-term horizon and active ownership: we commit capital where we can add value beyond the cheque, and we stay involved through board participation, operational support and strategic guidance.
Selected Investments
Case studies.
Velaris (formerly Markes International)
January 2026 · Undisclosed
Global leader in analytical technologies for pharmaceutical, food and environmental laboratories. Markes joins the Velaris ecosystem alongside Skalar Analytical, LCTech, PromoChrom, EST Analytical, GERSTEL and TE Instruments, reinforcing Velaris' position as a reference international scientific instrumentation platform specializing in GC-MS and sample-preparation automation.
Edelweiss Lab
Digital Therapeutics
An innovative smoking-cessation platform combining AI, personalized medical monitoring and behavioral therapy, delivering a success rate three times higher than traditional methods. Expansion across Europe and the Middle East is underway.
Technology Ventures
€127M deployed
A diversified technology portfolio of six companies spanning machine-learning infrastructure, Zero Trust cybersecurity, B2B sales-intelligence SaaS, developer tools, cloud infrastructure and FinTech APIs across France, the UK, Germany, Israel and the United States, from seed to Series C.
Alpine Luxury Collection
Part of €312M portfolio
An ultra-luxury Alpine portfolio including the Verbier Chalet Collection, Crans-Montana Penthouse Residences and a boutique Zermatt mountain resort, complemented by Mediterranean and urban prime holdings.
The Velaris instrumentation platform
Our January 2026 acquisition of Markes International, rebranded Velaris, anchors a growing scientific instrumentation platform. Alongside Skalar Analytical, LCTech, PromoChrom, EST Analytical, GERSTEL and TE Instruments, it gives Velaris a leadership position in analytical technologies for pharmaceutical, food and environmental laboratories, with particular strength in GC-MS and sample-preparation automation.
The strategy is consolidation with purpose: bring together complementary technologies under a single platform, invest in R&D and commercial reach, and serve laboratories worldwide with an integrated portfolio of leading instruments.
Digital health that works
Edelweiss Lab represents our conviction in clinically validated digital therapeutics. Its smoking-cessation platform combines artificial intelligence, personalized medical monitoring and behavioral therapy to deliver a success rate three times higher than traditional methods. Our Series B growth investment supports expansion across Europe and the Middle East.
It exemplifies the kind of healthcare opportunity we seek: measurable clinical outcomes, a defensible technology edge and a clear path to durable, responsible growth.
We commit capital where we can add value beyond the cheque, then stay involved.
Companies built, assets stewarded, held for the long term.
Our portfolio
Your company could be next.
We are always seeking exceptional companies and assets aligned with our thesis across our eight investment sectors.
Present Your Opportunity